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objective of this pharmacoeconomic analysis is to access the cost-
effectiveness of capecitabine compared to 5-FU/LV in the adju-
vant setting in Taiwan from the payer’s [Bureau of National
Health Insurance (BNHI)] perspective. METHODS: A state-
transition economic model was developed to estimate incremen-
tal cost impact and the effectiveness in terms of quality-adjusted
life months (QALMs). Clinical outcomes and medical resource
utilization were collected during the phase III X-ACT study.
Direct medical costs associated with chemotherapy drugs, physi-
cian consultations, and adverse events (AEs) management were
based on Taiwan’s National Health Insurance fee schedule. Intra-
venous chemotherapy administration costs and post-treatment
costs were estimated from an expert panel survey conducted
among 12 colorectal surgeons and medical oncologists. Health-
related utility scores were obtained from published literature.
Outcomes and future costs were discounted at 1.5% and 6%
respectively. Sensitivity analyses were performed on key model
parameters. RESULTS: Administration of capecitabine required
fewer physician visits per patient (7.4 versus 28.0 with 5-FU/LV).
Drug acquisition costs of capecitabine were higher than 5-FU/LV,
however, these cost increments were offset by the chemotherapy
administration cost of 5-FU/LV. In addition, more expensive
medications and longer hospitalization were needed to manage
5-FU/LV-related AEs. As a result, capecitabine demonstrated a
signiﬁcant overall cost savings of $104,546 NTD. Over a life-
time, the survival beneﬁt for capecitabine extends to 9 QALMs.
Capecitabine remained dominant under sensitivity testing. CON-
CLUSION: From a Taiwan BNHI perspective, this pharma-
coeconomic analysis showed that the use of capecitabine in
adjuvant treatment of colon cancer would not only save direct
medical costs but also improve health outcomes compared to 
5-FU/LV.
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OBJECTIVES: With 60 months of follow-up data now available
from the IRIS trial, we updated our previous cost-effectiveness
analysis of ﬁrst-line imatinib versus interferon-á plus cytarabine
(IFN) in newly diagnosed patients with chronic myeloid
leukemia in the chronic phase that was originally based on a
median of 19 months of follow-up. METHODS: We used the
empirical 60-month data from IRIS for patients randomized to
imatinib to calibrate the survival curves generated with the cost-
effectiveness model. Due to the high rate of crossover among
patients randomized to IFN in IRIS, we relied on historical data
to model survival estimates for patients treated with IFN. We
updated costs to 2006 values and applied two sets of costs to
imatinib and IFN: average wholesale prices (AWP) and whole-
sale acquisition costs (WAC). RESULTS: Survival at 5 years for
patients randomized to imatinib was better than predicted with
our original model (89.4% vs. 83.2%). After model calibration,
we estimated remaining life expectancy for ﬁrst-line imatinib
patients to be 19.1 years, an increase of 3.8 years over the orig-
inal model. Remaining quality-adjusted life-years (QALYs) were
estimated at 15.2, an increase of 3.1 QALYs. Estimates for
patients randomized to IFN were maintained at 9.1 years and
6.3 QALYs. With AWPs, ICERs ranged from $40,300 to
$57,100 per QALY when applying less and more conservative
assumptions about the duration of ﬁrst- and second-line treat-
ment with imatinib and IFN. With WACs, ICERs ranged from
$33,500 to $46,100 per QALY. CONCLUSION: Although our
analysis revealed that our initial survival estimates were conser-
vative, the updated ICERs were relatively consistent with our
original estimate of $43,300 per QALY. Periodically updating
cost-effectiveness analyses should be a routine practice in cases
where ongoing survival data are collected. Even with 5 years of
data, most of the expected survival beneﬁt has yet to be observed.
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OBJECTIVES: The PSALC is an instrument that was developed
for use in patients with SCLC for assessment of nine symptoms
(i.e., shortness of breath, cough, chest pain, hemoptysis, appetite
loss, sleep interference, hoarseness, fatigue, interference with
daily activities) scored on a scale from 1 (not at all) to 4 (very
much), but it has not been formally validated. METHODS: A
retrospective psychometric validation was conducted using data
from a randomized multicenter trial in which 107 patients with
SCLC were treated with intravenous topotecan and 104 patients
with cyclophosphamide, doxorubicin, and vincristine. PSALC
was administered to patients at baseline and at each of the four
subsequent clinical visits at 3-week intervals. Factor analysis
(FA), internal consistency, construct validity, reliability, and
responsiveness were evaluated. RESULTS: Baseline FA (n = 137)
indicated that there was only one factor, so the PSALC total score
was used for validation. Weighted Cronbach’s alpha from all
visits was 0.74 showing an acceptable internal consistency. 
Construct validity was supported by the high correlation with
established measures, with lower baseline PSALC total scores
associated with better Eastern Cooperative Oncology Group
(ECOG) performance status (12.41, 18.24, and 20.33 for ECOG
score = 0, 1, and 2, respectively, p < 0.0001; regression slope esti-
mate = 3.84, p < 0.0001; n = 135). Reliability was supported by
an intraclass correlation coefﬁcient of 0.61, calculated using
PSALC total scores evaluated before any change in clinical
status, and a concordance correlation coefﬁcient of 0.72, calcu-
lated using PSALC total scores at baseline and before the ﬁrst
visit. The PSALC total score was responsive to tumor progres-
sion (responsiveness statistic = 0.64; n = 33). CONCLUSION: A
retrospective analysis suggests that the PSALC is a reliable, valid,
and responsive instrument for measuring SCLC symptoms. If
feasible in this population, a prospective validation study could
be used to further evaluate these ﬁndings.
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OBJECTIVES: To evaluate trends in epoetin alfa (EPO) and 
darbepoetin alfa (DARB) dosing patterns and drug costs from
2005–2006 in elderly patients with pre-dialysis chronic kidney
disease (CKD) receiving care in nephrology clinics. METHODS:
A random panel of approximately 250 nephrologists was
requested to review the medical records of their two most
recently seen anemic pre-dialysis CKD patients who were receiv-
